Literature DB >> 31446001

Centromedian thalamic nuclei deep brain stimulation and Anakinra treatment for FIRES - Two different outcomes.

Mario Sa1, Rinki Singh2, Suresh Pujar1, Felice D'Arco3, Nivedita Desai1, Christin Eltze1, Elaine Hughes4, Muthana Al Obaidi5, Despina Eleftheriou6, Martin Tisdall7, Richard Selway8, J Helen Cross9, Marios Kaliakatsos10, Antonio Valentin2.   

Abstract

Febrile infection-related epilepsy syndrome (FIRES) is a severe epilepsy disorder that affects previously healthy children. It carries high likelihood of unfavourable outcome and putative aetiology relates to an auto-inflammatory process. Standard antiepileptic drug therapies including intravenous anaesthetic agents are largely ineffective in controlling status epilepticus in FIRES. Deep brain stimulation of the centromedian thalamic nuclei (CMN-DBS) has been previously used in refractory status epilepticus in only a few cases. The use of Anakinra (a recombinant version of the human interleukin-1 receptor antagonist) has been reported in one case with FIRES with good outcome. Here we describe two male paediatric patients with FIRES unresponsive to multiple anti-epileptic drugs, first-line immune modulation, ketogenic diet and cannabidiol. They both received Anakinra and underwent CMN-DBS. The primary aim for CMN-DBS therapy was to reduce generalized seizures. CMN-DBS abolished generalized seizures in both cases and Anakinra had a positive effect in one. This patient had a favourable outcome whereas the other did not. These are the first reported cases of FIRES where CMN-DBS has been used. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anakinra; Centromedian thalamic nuclei; Deep brain stimulation; FIRES

Mesh:

Substances:

Year:  2019        PMID: 31446001     DOI: 10.1016/j.ejpn.2019.08.001

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  13 in total

Review 1.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

2.  Responsive neurostimulation for focal motor status epilepticus.

Authors:  Jimmy C Yang; Nitish M Harid; Fábio A Nascimento; Vasileios Kokkinos; Abigail Shaughnessy; Alice D Lam; M Brandon Westover; Thabele M Leslie-Mazwi; Leigh R Hochberg; Eric S Rosenthal; Andrew J Cole; Robert M Richardson; Sydney S Cash
Journal:  Ann Clin Transl Neurol       Date:  2021-05-06       Impact factor: 4.511

3.  Whole-exome and HLA sequencing in Febrile infection-related epilepsy syndrome.

Authors:  Ingo Helbig; Giulia Barcia; Manuela Pendziwiat; Shiva Ganesan; Stefanie H Mueller; Katherine L Helbig; Priya Vaidiswaran; Julie Xian; Peter D Galer; Zaid Afawi; Nicola Specchio; Gerhard Kluger; Gregor Kuhlenbäumer; Silke Appenzeller; Michael Wittig; Uri Kramer; Andreas van Baalen; Rima Nabbout
Journal:  Ann Clin Transl Neurol       Date:  2020-07-14       Impact factor: 4.511

4.  Anakinra usage in febrile infection related epilepsy syndrome: an international cohort.

Authors:  Yi-Chen Lai; Eyal Muscal; Elizabeth Wells; Nikita Shukla; Krista Eschbach; Ki Hyeong Lee; Marios Kaliakatsos; Nevedita Desai; Ronny Wickström; Maurizio Viri; Elena Freri; Tiziana Granata; Srishti Nangia; Robertino Dilena; Andreas Brunklaus; Mark S Wainwright; Mark P Gorman; Coral M Stredny; Abdurhman Asiri; Khalid Hundallah; Asif Doja; Eric Payne; Elaine Wirrell; Sookyong Koh; Jessica L Carpenter; James Riviello
Journal:  Ann Clin Transl Neurol       Date:  2020-12-04       Impact factor: 5.430

5.  Case Report: Embedding "Digital Chronotherapy" Into Medical Devices-A Canine Validation for Controlling Status Epilepticus Through Multi-Scale Rhythmic Brain Stimulation.

Authors:  Mayela Zamora; Sebastian Meller; Filip Kajin; James J Sermon; Robert Toth; Moaad Benjaber; Derk-Jan Dijk; Rafal Bogacz; Gregory A Worrell; Antonio Valentin; Benoit Duchet; Holger A Volk; Timothy Denison
Journal:  Front Neurosci       Date:  2021-09-24       Impact factor: 4.677

6.  Deep brain stimulation of the centromedian thalamic nucleus for the treatment of FIRES.

Authors:  Jasmine L Hect; Luis D Fernandez; William P Welch; Taylor J Abel
Journal:  Epilepsia Open       Date:  2021-12-13

7.  Hypothesis: Febrile infection-related epilepsy syndrome is a microglial NLRP3 inflammasome/IL-1 axis-driven autoinflammatory syndrome.

Authors:  Wei-Sheng Lin; Ting-Rong Hsu
Journal:  Clin Transl Immunology       Date:  2021-06-14

Review 8.  Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy.

Authors:  Gaku Yamanaka; Yu Ishida; Kanako Kanou; Shinji Suzuki; Yusuke Watanabe; Tomoko Takamatsu; Shinichiro Morichi; Soken Go; Shingo Oana; Takashi Yamazaki; Hisashi Kawashima
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

Review 9.  The off-label use of anakinra in pediatric systemic autoinflammatory diseases.

Authors:  Valerio Maniscalco; Sarah Abu-Rumeileh; Maria Vincenza Mastrolia; Edoardo Marrani; Ilaria Maccora; Ilaria Pagnini; Gabriele Simonini
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-16       Impact factor: 5.346

10.  Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop.

Authors:  Sookyong Koh; Elaine Wirrell; Annamaria Vezzani; Rima Nabbout; Eyal Muscal; Marios Kaliakatsos; Ronny Wickström; James J Riviello; Andreas Brunklaus; Eric Payne; Antonio Valentin; Elizabeth Wells; Jessica L Carpenter; Kihyeong Lee; Yi-Chen Lai; Krista Eschbach; Craig A Press; Mark Gorman; Coral M Stredny; William Roche; Tara Mangum
Journal:  Epilepsia Open       Date:  2021-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.